Yousif Capital Management LLC Sells 2,151 Shares of Bruker Co. (NASDAQ:BRKR)

Yousif Capital Management LLC cut its position in Bruker Co. (NASDAQ:BRKR) by 5.2% in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 39,183 shares of the medical research company’s stock after selling 2,151 shares during the quarter. Yousif Capital Management LLC’s holdings in Bruker were worth $2,879,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in BRKR. Lindbrook Capital LLC boosted its position in shares of Bruker by 68.2% in the fourth quarter. Lindbrook Capital LLC now owns 360 shares of the medical research company’s stock valued at $26,000 after acquiring an additional 146 shares during the period. VisionPoint Advisory Group LLC raised its stake in Bruker by 145.0% in the 3rd quarter. VisionPoint Advisory Group LLC now owns 512 shares of the medical research company’s stock worth $32,000 after purchasing an additional 303 shares in the last quarter. GAMMA Investing LLC bought a new stake in Bruker in the 4th quarter valued at about $33,000. Fifth Third Bancorp grew its position in shares of Bruker by 53.3% during the 3rd quarter. Fifth Third Bancorp now owns 541 shares of the medical research company’s stock worth $34,000 after purchasing an additional 188 shares in the last quarter. Finally, Life Planning Partners Inc bought a new position in shares of Bruker during the fourth quarter worth approximately $44,000. 79.52% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling at Bruker

In other news, Director Hermann Fritz Requardt sold 15,000 shares of the business’s stock in a transaction dated Monday, March 4th. The stock was sold at an average price of $90.06, for a total transaction of $1,350,900.00. Following the sale, the director now directly owns 23,147 shares in the company, valued at $2,084,618.82. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Corporate insiders own 28.20% of the company’s stock.

Analysts Set New Price Targets

BRKR has been the subject of several recent research reports. JPMorgan Chase & Co. upgraded Bruker from a “neutral” rating to an “overweight” rating and boosted their price target for the company from $60.00 to $90.00 in a research note on Wednesday, February 14th. UBS Group upped their target price on Bruker from $94.00 to $102.00 and gave the company a “buy” rating in a research report on Friday, March 1st. The Goldman Sachs Group raised their price target on Bruker from $66.00 to $74.00 and gave the stock a “sell” rating in a research report on Wednesday, April 10th. Stifel Nicolaus upped their price objective on shares of Bruker from $63.00 to $81.00 and gave the stock a “hold” rating in a research report on Wednesday, February 14th. Finally, Citigroup raised their target price on shares of Bruker from $80.00 to $95.00 and gave the company a “buy” rating in a report on Wednesday, February 14th. One analyst has rated the stock with a sell rating, two have given a hold rating and five have given a buy rating to the company. According to MarketBeat, Bruker presently has a consensus rating of “Moderate Buy” and an average target price of $84.86.

Bruker Trading Up 0.5 %

BRKR opened at $80.97 on Monday. The company has a market cap of $11.77 billion, a P/E ratio of 27.73, a PEG ratio of 2.05 and a beta of 1.17. The company has a current ratio of 1.80, a quick ratio of 0.99 and a debt-to-equity ratio of 0.83. The company’s 50 day moving average is $88.08 and its 200-day moving average is $74.76. Bruker Co. has a 1-year low of $53.79 and a 1-year high of $94.86.

Bruker (NASDAQ:BRKR) last issued its quarterly earnings data on Tuesday, February 13th. The medical research company reported $0.70 EPS for the quarter, beating the consensus estimate of $0.65 by $0.05. The business had revenue of $844.50 million during the quarter, compared to the consensus estimate of $809.35 million. Bruker had a net margin of 14.41% and a return on equity of 29.94%. The firm’s revenue was up 19.2% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $0.74 EPS. Equities research analysts predict that Bruker Co. will post 2.74 earnings per share for the current fiscal year.

Bruker Announces Dividend

The company also recently announced a quarterly dividend, which was paid on Friday, March 15th. Shareholders of record on Friday, March 1st were issued a $0.05 dividend. The ex-dividend date of this dividend was Thursday, February 29th. This represents a $0.20 dividend on an annualized basis and a yield of 0.25%. Bruker’s payout ratio is presently 6.85%.

Bruker Profile

Bruker Corporation, together with its subsidiaries, develops, manufactures, and distributes scientific instruments, and analytical and diagnostic solutions in the United States, Europe, the Asia Pacific, and internationally. The company operates through four segments: Bruker Scientific Instruments (BSI) BioSpin, BSI CALID, BSI Nano, and Bruker Energy & Supercon Technologies.